Public, NASDAQ:DNDN
NASDAQ Global Market
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Date: Thu, 24 Jul 2008 17:13:43 GMT
Tags:
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
UroToday - 19 hours ago
UroToday - 19 hours ago
SEATTLE , WA , USA ( Press Release ) - July 23 , 2008 - Dendreon Corporation ( Nasdaq : DNDN ) today announced that it expects the Independent Data Monitoring Committee ( IDMC ) to review in ...
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Date: Wed, 23 Jul 2008 19:20:46 GMT
Tags:
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
FOXBusiness - Jul 23, 2008
FOXBusiness - Jul 23, 2008
SEATTLE , July 23 , 2008 / PRNewswire - FirstCall via COMTEX / - - - - Dendreon Corporation ( Nasdaq : DNDN ) today announced that it expects the Independent Data Monitoring Committee ( IDMC ...
Dendreon expects Provenge results in October
Date: Wed, 23 Jul 2008 16:40:50 GMT
Tags:
Dendreon expects Provenge results in October
Seattle Post Intelligencer - Jul 23, 2008
Seattle Post Intelligencer - Jul 23, 2008
Dendreon said this morning that it expects to receive the interim results of a trial of its Provenge prostate cancer treatment this October.The FDA has indicated that if the interim results are ...
Dendreon Expects review of Interim Data Analysis of Phase 3 Provenge Trial in October - Quick Facts
Date: Wed, 23 Jul 2008 14:13:20 GMT
Tags:
Dendreon Expects review of Interim Data Analysis of Phase 3 Provenge Trial in October - Quick Facts
RTT News - Jul 23, 2008
RTT News - Jul 23, 2008
( RTTNews ) - Dendreon Corp . ( DNDN : News , Chart , Quote ) said it expects the Independent Data Monitoring Committee to review the interim analysis of overall survival relating to its Phase ...
Market Report -- In Play (DNDN)
Date: Wed, 23 Jul 2008 12:18:00 GMT
Tags:
Market Report -- In Play (DNDN)
MSN Money - Jul 23, 2008
MSN Money - Jul 23, 2008
Dendreon expects interim data analysis for Phase 3 PROVENGE IMPACT trial in October Co announces that it expects the Independent Data Monitoring Committee to review in October 2008 the interim ...
Anadigics, UAL Corp and Dendreon lead small-cap volume in pre-market (SmallCapInvestor.com)
Date: Wed, 23 Jul 2008 13:27:09 Etc/GMT
Tags:
Here are the most actively traded companies among small caps:
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October (PR Newswire)
Date: Wed, 23 Jul 2008 11:30:00 Etc/GMT
Tags:
Dendreon Corporation today announced that it expects the Independent Data Monitoring Committee to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT clinical trial of PROVENGE® .
Invest in Biovest? (at Minyanville.com)
Date: Fri, 18 Jul 2008 16:45:00 Etc/GMT
Tags:
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery (PR Newswire)
Date: Wed, 16 Jul 2008 11:30:00 Etc/GMT
Tags:
Dendreon Corporation today announced that the Company has initiated a Phase 2 trial of PROVENGE® , Dendreon's investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled to undergo a radical prostatectomy.
Dendreon Reliant on One Drug (Zacks.com)
Date: Tue, 15 Jul 2008 14:32:56 Etc/GMT
Tags: